CCRA Investigational Product Management 3

Question 1

Which document formally authorizes a site to begin receiving and storing investigational product?

Accepted Answer

A confirmed IRB approval letter, signed protocol, and completed 1572, with sponsor confirmation of site activation

Answer

The Site Initiation Visit report

Answer

The Clinical Trial Agreement (financial contract)

Answer

The CRA's monitoring plan

Question 2

When a clinical trial uses an interactive response technology (IRT/IVRS/IWRS) system for randomization and IP management, the system's primary functions include:

Accepted Answer

Managing subject randomization, treatment assignment, and investigational product dispensing and resupply logistics

Answer

Generating adverse event reports automatically

Answer

Submitting regulatory documents to the FDA

Answer

Tracking site monitoring visit schedules

Question 3

A 'comparator product' in a clinical trial refers to:

Accepted Answer

An approved product (or placebo) used as a reference against which the investigational product is evaluated

Answer

A placebo without active ingredients

Answer

A generic version of the investigational product

Answer

A backup supply of investigational product

Question 4

Site staff may not open or break the blind of randomization codes except:

Accepted Answer

When medically necessary for subject safety (e.g., medical emergency) following the pre-defined emergency unblinding procedure

Answer

When a subject requests to know their treatment assignment

Answer

When the CRA requests unblinding during a monitoring visit

Answer

After enrollment of the first 10 subjects for interim safety review

Question 5

When investigational product is transferred between two investigational sites, which step is MOST critical?

Accepted Answer

Obtaining sponsor approval and ensuring complete chain of custody documentation with temperature monitoring during transfer

Answer

Ensuring the receiving site has a lower temperature during transit

Answer

Allowing the CRA to transport the product during a monitoring visit

Answer

Confirming both sites are in the same city

Question 6

Which of the following best describes 'open-label' trial design with respect to investigational product management?

Accepted Answer

Both subjects and investigators know which treatment is being administered, with no blinding of treatment assignment

Answer

IP is provided with no label or identification

Answer

Only the subject is unblinded while the investigator remains blinded

Answer

The IP label includes the subject's name publicly